NEWS HIGHLIGHTSMedia Articles Related to Comtan (Entacapone)
Dietary Nicotine In Peppers May Reduce Risk Of Developing Parkinson's Disease
Source: Nutrition / Diet News From Medical News Today [2013.05.12]
New research reveals that Solanaceae - a flowering plant family with some species producing foods that are edible sources of nicotine - may provide a protective effect against Parkinson's disease...
Muhammad Ali's Daughter Champions Fight Against Parkinson's Disease
Source: MedicineNet Clinical Trials Specialty [2013.05.03]
Title: Muhammad Ali's Daughter Champions Fight Against Parkinson's Disease
Category: Health News
Created: 5/3/2013 10:35:00 AM
Last Editorial Review: 5/3/2013 12:00:00 AM
Incurable Neurological Disorder HDLS Often Incorrectly Diagnosed As Alzheimer's Disease, MS Or Parkinson's Disease
Source: Multiple Sclerosis News From Medical News Today [2013.04.13]
The very serious hereditary disease HDLS was discovered in 1984 in Sweden. Many HDLS patients are still incorrectly diagnosed with Alzheimer's disease, MS or Parkinson's disease, but researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have now developed a more certain diagnosis method - and are seeking to find a treatment for the "unknown" neurological disorder...
Key Initiator To Prion And Parkinson's Disease Is Likely Brain Inflammation
Source: CJD / vCJD / Mad Cow Disease News From Medical News Today [2012.12.03]
Prion diseases represent a family of neurodegenerative disorders associated with the loss of brain cells and caused by proteins called prions (derived from 'protein' and 'infection'). The diseases are found in both humans and animals, such as Creutzfeld-Jakob disease and mad cow disease respectively...
Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet amantadine Specialty [2011.08.31]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 8/31/2011 2:27:29 PM
Published Studies Related to Comtan (Entacapone)
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. [2011.01]
OBJECTIVE: In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability. The COMT Val158Met polymorphism is equally distributed in PD patients and modulates COMT activity, which can be high (Val/Val, COMT(HH) ), intermediate (Val/Met, COMT(HL) ), or low (Met/Met, COMT(LL) ). The objective of this study was to determine the response to entacapone in COMT(HH) and COMT(LL) PD patients... INTERPRETATION: The COMT(HH) genotype in PD patients enhances the effect of entacapone on the pharmacodynamics and pharmacokinetics of levodopa. The response to entacapone after repeated administrations and in heterozygous patients remains to be determined. Copyright (c) 2010 American Neurological Association.
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. [2011.01]
BACKGROUND: L-threo-3,4-dihydroxyphenylserine (L-DOPS), a norepinephrine (NE) prodrug, is investigational for orthostatic hypotension, which occurs commonly in Parkinson's disease. Adjunctive anti-parkinsonian drugs might interact with L-DOPS. We tested whether L-aromatic amino-acid decarboxylase inhibition by carbidopa (CAR) attenuates L-DOPS conversion to NE and blocks the pressor effect of L-DOPS, whereas catechol-O-methyltransferase inhibition by entacapone (ENT) interferes with L-DOPS metabolism and augments the pressor effect... CONCLUSIONS: After L-DOPS administration plasma, NE levels do not increase sufficiently to increase blood pressure. Pressor responses to L-DOPS seem to reflect NE produced extraneuronally that escapes extensive enzymatic deamination and O-methylation and evokes vasoconstriction before reaching the systemic circulation.
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine
prodrug L-DOPS. [2011]
interferes with L-DOPS metabolism and augments the pressor effect... CONCLUSIONS: After L-DOPS administration plasma, NE levels do not increase
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. [2010.11]
OBJECTIVE: Controlled-release levodopa/carbidopa (CR-LC) is often used to provide prolonged control of night-time motor symptoms in patients with Parkinson's disease (PD). Levodopa/carbidopa/entacapone (LCE) provides higher bioavailability of levodopa compared with levodopa/carbidopa formulations and has been shown to be effective in PD patients with wearing-off symptoms. The aim of this study was to compare the bioavailability of levodopa after a single evening dose (administered at 10 p.m.) of LCE 200 or CR-LC 200... CONCLUSIONS: The results of this study demonstrate that a single bedtime dose of LCE 200 provides higher bioavailability of levodopa compared to CR-LC 200.
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. [2010.07]
OBJECTIVE: L-dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications in the majority of patients. It has been hypothesized that providing more continuous delivery of L-dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L-dopa with entacapone, an inhibitor of catechol-O-methyltransferase, to extend its elimination half-life... INTERPRETATION: Initiating L-dopa therapy with LCE failed to delay the time of onset or reduce the frequency of dyskinesia compared to LC. In fact, LCE was associated with a shorter time to onset and increased frequency of dyskinesia compared to LC. These results may reflect that the treatment protocol employed did not provide continuous L-dopa availability and the higher L-dopa dose equivalents in the LCE group.
Clinical Trials Related to Comtan (Entacapone)
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers [Completed]
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers [Completed]
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers [Completed]
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers [Completed]
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-Motor Symptoms in Patients With Idiopathic Parkinson's Disease [Recruiting]
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to
the effects of immediate-release carbidopa/levodopa on end-of-dose wearing off in persons who
have Parkinson's disease.
Reports of Suspected Comtan (Entacapone) Side Effects
Dysphagia (8),
Pain in Extremity (8),
Blood Creatine Phosphokinase Increased (6),
Parkinson's Disease (6),
Abnormal Behaviour (6),
Dyskinesia (5),
Muscle Spasms (5),
Chromaturia (5),
Akinesia (5),
Tremor (5), more >>
|
